Patents Assigned to Pfizer
  • Patent number: 5056715
    Abstract: An apparatus for mixing and spraying a slurry. The apparatus comprises a housing including a channel. The channel is in fluid communication with an inlet at its upstream end and curves to an outlet at its downstream end. The outlet is in fluid communication with an air atomization nozzle. A mixing surface is capable of rotation with respect to the housing and the channel is open to the mixing surface.
    Type: Grant
    Filed: February 21, 1990
    Date of Patent: October 15, 1991
    Assignee: Pfizer Inc.
    Inventor: Richard W. Korsmeyer
  • Patent number: 5057626
    Abstract: A process for the synthesis of alpha,alpha-difluoroketones from alpha,alpha-difluoroacylsilanes and intermediates therefor.
    Type: Grant
    Filed: October 1, 1990
    Date of Patent: October 15, 1991
    Assignee: Pfizer Inc.
    Inventor: Peter A. McCarthy
  • Patent number: 5055473
    Abstract: A series of novel N-alkyl-N-(alkanesulphonamidoheterocyclicmethyl) -4-alkanesulphonamidophenethylamines have been prepared, including their pharmaceutically acceptable salts and various key novel intermediates therefor. The heterocyclic moiety present in these compounds is a benzo-fused heterocyclic group derived from either benzofuran, benzothiophene, benzoxazole or quinoline, and it is attached to the adjacent methyl group of the molecule by means of the available ring carbon atom which is situated alpha to the hetero atom. These particular compounds are useful in therapy as highly effective anti-arrhythmic agents and therefore, are of value in the treatment of various cardiac arrhythmias. Preferred member compounds include N-methyl-N-(5-methanesulphonamidobenzofur-2-ylmethyl)-4 -methanesulphonamidophenethylamine and N-methyl-N-(6- methanesulphonamidoquinol-2-ylmethyl)-4-methane-sulphonamidophenethylamine . Methods for preparing all these compounds from known starting materials are provided.
    Type: Grant
    Filed: May 29, 1990
    Date of Patent: October 8, 1991
    Assignee: Pfizer Inc.
    Inventors: John E. Arrowsmith, Peter E. Cross, Geoffrey N. Thomas
  • Patent number: 5051412
    Abstract: Compounds of the formula ##STR1## wherein one of A, B, D and E is N and the remaining three atoms are C; R.sup.1 and R.sup.2 are independently selected from hydrogen and C.sub.1 to C.sub.6 alkyl; and R.sup.3, R.sup.4, R.sup.5 and R.sub.6 are independently selected from hydrogen, halogen, hydroxy, C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.8 alkoxy, phenyl-C.sub.1 -C.sub.6 alkoxy, phenoxy --NR.sup.7 R.sup.8 wherein R.sup.7 and R.sup.8 are independently selected from hydrogen, C.sub.1 -C.sub.8 alkyl, C.sub.1 -C.sub.6 alkanoyl and COOR.sup.9 wherein R.sup.9 is hydrogen or C.sub.1 -C.sub.6 alkyl, cyano, COOR.sup.10 wherein R.sup.10 is hydrogen or C.sub.1 -C.sub.6 alkyl, and CONR.sup.11 R.sup.12 where R.sup.10 and R.sup.11 are independently selected from hydrogen and C.sub.1 -C.sub.6 alkyl, and the pharmaceutically acceptable salts thereof. The compounds are useful psychotherapeutics and may be used in treating obesity, depression and disorders wherein aggression is a symptom.
    Type: Grant
    Filed: September 17, 1990
    Date of Patent: September 24, 1991
    Assignee: Pfizer Inc.
    Inventor: John E. Macor
  • Patent number: 5047548
    Abstract: Compounds of the formula ##STR1## or a pharmaceutically or agriculturally acceptable acid addition salt thereof, wherein R is 5-chloro-2-pyridyl, or phenyl optionally substituted by one to three substituents, each independently selected from F, Cl, Br, I, CF.sub.3, C.sub.1 -C.sub.4 alkyl and C.sub.1 -C.sub.4 alkoxy; R.sup.1 is CN, CSNH.sub.2 or CONR.sup.2 R.sup.3 where either(a) R.sup.2 is H or certain alkyl groups and R.sup.3 is H or certain alkyl, substituted alkyl, aralkyl, phenyl or cycloalkyl groups, or(b) R.sup.2 and R.sup.3 taken together with the nitrogen atom to which they are attached form a nitrogen heterocyclic group, optionally containing an oxygen atom or NR.sup.4 group, as a ring member and R.sup.4 is H, C.sub.1 -C.sub.4 alkyl; C.sub.2 -C.sub.4 alkanoyl or (C.sub.1 -C.sub.4 alkoxy)carbonyl;R.sup.5 and R.sup.6 are each H or CH.sub.
    Type: Grant
    Filed: January 27, 1988
    Date of Patent: September 10, 1991
    Assignee: Pfizer Inc.
    Inventors: Kenneth Richardson, Geoffrey E. Gymer
  • Patent number: 5047056
    Abstract: A canine hip prosthesis with a porous coating for bone ingrowth is disclosed. The femoral prosthesis generally comprises a stem for insertion into the intramedullary canal of a canine femur which stem is divided into a proximal portion and a longer distal portion. The stem exhibits a compound curvature along its length, including a slight posterior bow, which provides the prosthesis with a glove-like fit in the prepared intramedullary canal of the canine femur. Provided on the proximal portion of the stem is a porous coating which generally comprises two layers of ball-shaped metallic particles bonded together at their points of contact, e.g. by sintering, which define between themselves a plurality of connected interstitial pores. The size of the particles is from -30 to +35 U.S. Standard mesh size, and the pore size is between about 0.014 and 0.020 inches.
    Type: Grant
    Filed: February 16, 1990
    Date of Patent: September 10, 1991
    Assignee: Pfizer, Inc.
    Inventor: Robert V. Kenna
  • Patent number: 5047055
    Abstract: A prosthetic nucleus for a vertebral disc is made of a hydrogel material. The hydrogel prosthetic nucleus has a shape generally conforming to the natural nucleus pulposus. The hydrogel has a water content of at least 30% and has a compressive strength of 4MNm.sup.-2 or greater. When the hydrogel material is dehydrated, it has a dimension of less than half of that of the hydrated hydrogel nucleus. The prosthetic nucleus may be formed of two or more pieces of hydrogel material which pieces, when combined, have a shape generally conforming to the natural nucleus.
    Type: Grant
    Filed: December 21, 1990
    Date of Patent: September 10, 1991
    Assignee: Pfizer Hospital Products Group, Inc.
    Inventors: Qi-Bin Bao, Paul A. Higham
  • Patent number: 5047554
    Abstract: This invention relates to novel 3-substituted-2-oxindole derivatives which are inhibitors of prostaglandin H.sub.2 synthase, 5-lipoxygenase and interleukin-1 biosynthesis. The compounds of the invention are useful as inhibitors of prostaglandin H.sub.2 synthase and interleukin-1 biosynthesis, per se, and as analgesic, antiinflammatory and antiarthritic agents in the treatment of chronic inflammatory diseases. This invention also relates to pharmaceutical compositions comprising said 3-substituted-2-oxindole derivatives; to methods of inhibiting prostaglandin H.sub.2 synthase and biosynthesis of interleukin-1; and to treating chronic inflammatory diseases in a mammal with said compounds. Further, this invention relates to certain novel carboxylic acids useful as intermediates in the preparation of the 3-substituted-2-oxindole derivatives of this invention and to a process for the preparation of the 3-substituted-2-oxindole derivatives.
    Type: Grant
    Filed: January 31, 1990
    Date of Patent: September 10, 1991
    Assignee: Pfizer Inc.
    Inventors: Frederick J. Ehrgott, Carl J. Goddard, Gary R. Schulte
  • Patent number: 5043017
    Abstract: A form of calcium carbonate, acid-stabilized by the addition to finely divided calcium carbonate of one of a calcium- chelating agent and a conjugate base, such as sodium hexametaphosphate, followed by the addition of a weak acid, such as phosphoric acid, is disclosed. A process for producing this material, and a method for its use in the making of neutral to acidic paper in order to improve the optical properties of the paper are also disclosed.
    Type: Grant
    Filed: March 9, 1990
    Date of Patent: August 27, 1991
    Assignee: Pfizer Inc.
    Inventor: June D. Passaretti
  • Patent number: 5041114
    Abstract: A modular femoral internal implant system for use in the treatment of femoral disorders resulting from injury, disease or congenital defect includes at least three interconnectable components: 1) an elongated epiphyseal/metaphyseal implant, 2) an intramedullary rod and 3) an angled side plate having an elongated plate portion adapted to be secured to the outer cortical wall and a hollow sleeve adapted to extend into the femur. The epiphyseal/metaphyseal implant can be connected to either the angled side plate or the intramedullary rod. The system may also include an elongated bone plate connectable to the angled side plate, one or more additional epiphyseal/metaphyseal implants of variable length, an additional angled side plate, a distal buttress plate connectable to the elongated bone plate, and a plurality of bone screws of a universal design. Preferably, many or all of the components of the system are made of an inert, resilient titanium-base alloy.
    Type: Grant
    Filed: August 15, 1988
    Date of Patent: August 20, 1991
    Assignee: Pfizer Hospital Products Group, Inc.
    Inventors: Michael W. Chapman, Charles C. Edwards, Dana C. Mears
  • Patent number: 5039683
    Abstract: Compounds of the formula ##STR1## wherein R.sup.1 is hydrogen, alkyl of 1 to 6 carbon atoms, or NR.sup.4 R.sup.5, wherein R.sup.4 and R.sup.5 are independently selected from hydrogen and alkyl of 1 to 6 carbon atoms or a pharmaceutically acceptable cation;R.sup.2 is hydrogen, hydroxy, alkanoylamino of 1 to 6 carbon atoms, morpholino, halogen, hydroxyalkyl of 1 to 6 carbon atoms, COOR.sup.6 wherein R.sup.6 is alkyl of 1 to 6 carbon atoms or a pharmaceutically acceptable cation, alkoxy of 1 to 6 carbon atoms, NR.sup.7 R.sup.8 wherein R.sup.7 and R.sup.8 are independently selected from alkyl of 1 to 6 carbon atoms, alkanoyl of 1 to 6 carbon atoms, hydrogen, alkoxy of 1 to 6 carbon atoms, aminoalkyl of 2 to 6 carbon atoms, alkylaminoalkyl wherein each alkyl group is independently selected from alkyl groups having 2 to 6 carbon atoms, and dialkylaminoalkyl wherein each alkyl group is independently selected from alkyl groups having one to six carbon atoms, with the proviso that only one of R.sup.7 and R.sup.
    Type: Grant
    Filed: May 31, 1989
    Date of Patent: August 13, 1991
    Assignee: Pfizer Inc.
    Inventor: Susumu Nakanishi
  • Patent number: 5039682
    Abstract: This invention relates to novel 1,7-disubstituted-6-fluoro-1,4-dihydroquinol-4-one-3-carboxylic acid derivatives and certain esters and cation salts thereof. This invention further relates to preparation of the compounds, antibacterial compositions containing the compounds and methods of using the compounds.This invention also relates to a novel process for preparing novel N-cyclopropyl intermediates useful for preparing certain of the 1,7-disubstituted-6-fluoro-1,4-dihydroquinol-4-one-3-carboxylic acid derivatives of this invention which contain a cyclopropyl substituent at the 1 position as well as other 1,4-dihydroquinol-4-one-3-carboxylic acid derivatives so substituted with cyclopropyl.
    Type: Grant
    Filed: June 21, 1988
    Date of Patent: August 13, 1991
    Assignee: Pfizer Inc.
    Inventor: Paul R. McGuirk
  • Patent number: 5039672
    Abstract: Certain spirocyclic heterocyclic compounds, and their pharmaceutically-acceptable salts, are inhibitors of the aldose reductase enzyme, and so are useful for the control of diabetic complications. Exemplary compounds include compounds of the formula ##STR1## wherein Y is ##STR2## X is --O-- or ##STR3## R.sub.1 and R.sub.2 are each independently H, alkyl C.sub.1 -C.sub.6,aryl or arylalkyl (C.sub.1 -C.sub.6);W.sub.1 and W.sub.2 are each independently hydrogen, halogen or nitro; andthe pharmaceutically acceptable base addition salts thereof.
    Type: Grant
    Filed: April 5, 1990
    Date of Patent: August 13, 1991
    Assignee: Pfizer Inc.
    Inventors: James F. Eggler, Eric R. Larson
  • Patent number: 5037842
    Abstract: A series of 5-(4-[2-substituted benzoxazolylmethoxy]benzyl)oxa- and thiazolidine-2,4-diones as antidiabetic and cholesterol lowering agents.
    Type: Grant
    Filed: June 5, 1990
    Date of Patent: August 6, 1991
    Assignee: Pfizer Inc.
    Inventor: Steven W. Goldstein
  • Patent number: 5037846
    Abstract: This invention relates to certain polyamines found to be present in the venom of the Agelenopsis aperta spider. The polyamines of this invention and the salts thereof antagonize excitatory amino acid neurotransmitters, which neurotransmitters affect cells of various organisms, and are useful in antagonizing said neurotransmitters, per se, in the treatment of excitatory amino acid neurotransmitter mediated diseases and conditions and in the control of invertebrate pests. This invention also relates to compositions comprising said polyamines and salts thereof.
    Type: Grant
    Filed: July 31, 1990
    Date of Patent: August 6, 1991
    Assignee: Pfizer Inc.
    Inventors: Nicholas A. Saccomano, Robert A. Volkmann
  • Patent number: 5037423
    Abstract: A novel method for replacing a previously implanted knee joint prosthesis in a patient is disclosed in which the previously implanted femoral component is replaced with a revision femoral component having thicker distal and posterior bearing portions so as to restore the natural anatomic transverse joint plane and collateral ligamentous balance in extension and flexion of the prosthetic joint. Instrumentation for use in this method includes a novel revision cutting jig which is used in the preparation of the distal end of the femur for the implantation of the revision femoral component.
    Type: Grant
    Filed: May 7, 1990
    Date of Patent: August 6, 1991
    Assignee: Pfizer Hospital Products Group, Inc.
    Inventor: Robert V. Kenna
  • Patent number: 5037834
    Abstract: 1-Substituted-6-fluoro-7-heterocyclic-1,4-dihydroquino-1-(or dihydronaphthyridin)-4-one carboxylic acids have antibacterial properties. The 7-heterocyclic group is a bicyclic group, one of the rings of which is saturated and the other ring of which is unsaturated.
    Type: Grant
    Filed: August 1, 1989
    Date of Patent: August 6, 1991
    Assignee: Pfizer Inc.
    Inventors: Katherine E. Brighty, John A. Lowe, III, Paul R. McGuirk
  • Patent number: 5036104
    Abstract: 2-Acylaminoalkyl-3-[1-(carboxycycloalkylcarbamoyl)cycloalkyl]propanoic acid derivatives (which may also be viewed as glutaramide derivatives) are useful in the treatment of hypertension, heart failure and renal insufficiency, based upon their inhibition of zinc-dependent, neutral endopiptidase.
    Type: Grant
    Filed: June 14, 1990
    Date of Patent: July 30, 1991
    Assignee: Pfizer Inc.
    Inventors: John C. Danilewicz, Keith James
  • Patent number: 5036088
    Abstract: Compounds of the formula ##STR1## where Y is alkyl, aryl or heterocyclic, n is 1-7, R is hydrogen, alkyl, aralkyl or carboxymethyl, R.sub.1 is acetoxy, thiophenoxy, hydrogen, halo, alkyl, alkoxy or trifluoromethyl, R.sub.2 is hydrogen, alkyl or alkanoyl and X is C.dbd.O, CH.sub.2, NH, O or S as antiallergy and antiinflammatory agents.
    Type: Grant
    Filed: December 3, 1990
    Date of Patent: July 30, 1991
    Assignee: Pfizer Inc.
    Inventors: Yoshihiko Kitaura, Fumitaka Ito, Rodney W. Stevens, Nobuko Asai
  • Patent number: 5036099
    Abstract: Anhydrous, crystalline sodium salt of 5-chloro-3-(2-thenoyl)-2-oxindole-1-carboxamide having advantageous properties for formulation as an analgesic or antiinflammatory agent.
    Type: Grant
    Filed: July 18, 1989
    Date of Patent: July 30, 1991
    Assignee: Pfizer Inc.
    Inventors: Douglas J. M. Allen, Brian T. O'Neill